Ypsomed Archives - Medical Design Sourcing

Ypsomed: closed-loop insulin dosing improves health of pregnant women with type 1 diabetes

A study showed that the mylife Loop system improves the health of pregnant women with type 1 diabetes. [image courtesy of Ypsomed]Ypsomed today announced clinical study data demonstrating the benefits of its hybrid closed-loop insulin delivery system for pregnant women.

Pregnant women with type 1 diabetes and their babies benefitted from the automated insulin delivery system based on the CamDiab CamAPS FX algorithm. The New England Journal of Medicine published these outcomes from Ypsomed’s AiDAPT clinical study.

Ypsomed says the CamAPS FX is the only automated insulin delivery (AID) algorithm approved for pregnant women with type 1 diabetes. The mylife Loop system combines that algorithm with the Ypsomed YpsoPump and the Abbott FreeStyle Libre 3 or Dexcom G6 CGM.

Together, they form an intelligent and automated insulin delivery (AID) system for people with type 1 diabetes. Users can better control glucose levels and alleviate the burden of daily diab…

Ypsomed has a new CFO, board member

Samuel Künzli

Ypsomed announced today that it selected Samuel Künzli to take over the company’s chief financial officer (CFO) position.

Niklaus Ramseier elected to hand over the reins to the CFO position after more than 20 years in the post. The transition begins on March 31, 2024, with Ramseier remaining available to the drug delivery device maker for strategic projects. Künzli begins as CFO on April 1, 2024.

Get the full story at our sister site, Drug Delivery Business News.

Ypsomed concludes autoinjector supply deal with Novo Nordisk

The YpsoMate 1mL autoinjector. [Image from Ypsomed]Ypsomed announced today that it concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors.

Burgdorf, Switzerland-based Ypsomed designed the autoinjectors to administer drugs for the self-treatment of metabolic conditions. It intends to deliver variants of its YpsoMate 1mL autoinjector for various drugs undergoing clinical trials in large quantities. This expands its manufacturing capacities over the coming years.

Novo Nordisk expects to contribute a significant part of the investment for additional production infrastructure. The companies expect availability of a significant capacity of autoinjectors for Novo Nordisk “in the course of 2025.”

Get the full story at our sister site, Drug Delivery Business News.

8 drug delivery innovations you should know

Innovations in drug delivery never stop and, over the past 12 months or so, a wide variety have come under the spotlight.

Constant progress continues in the diabetes space, both in the form of insulin delivery and other drug delivery methods. Elsewhere, we see implants, patches, syringes and more showcasing just how many ways we can deliver therapeutics.

About a year ago, we clued in readers to a list of six drug delivery innovations they should know. Here, we provide a couple of updates on those and try to introduce a few more developments that you should know:

The latest in automated insulin delivery tech

Automated insulin delivery represents one of the most high-profile markets in drug delivery, with the technology providing potentially life-saving therapy for people with diabetes.

The Mobi automated insulin pump with the accompanying mobile app. [Image courtesy of Tandem Diabetes Care]Last year’s roundup included the already FDA-cleared Omn…

Ypsomed to expand drug delivery device manufacturing, add 200 jobs

Ypsomed announced today that, at its annual general meeting, its shareholders approved all proposals, including facility expansions.

Burgdorf, Switzerland-based Ypsomed develops drug delivery devices, including insulin pumps for those with diabetes. Its YpsoPump represents a leading offering as an automated insulin delivery system compatible with certain software and glucose monitors.

Board member Simon Michel confirmed the company’s commitment to Switzerland as a manufacturing location at the annual meeting. Ypsomed expects to create 200 new jobs in Burgdorf and Solothurn in the current financial year, on top of expansions elsewhere.

Get the full story at our sister site, Drug Delivery Business News.

Ypsomed, S3 Connected Health partner to expand digital offerings

[Image courtesy of Ypsomed and S3 Connected Health]

Ypsomed announced plans to expand its offerings of digital health solutions for chronic disease therapy together with S3 Connected Health.

Dublin, Ireland-based S3 Connected Health specializes as a digital health partner for life science companies. This partnership allows Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. It enables therapy management support for acute and chronic diseases while enhancing outcomes.

Ypsomed said in a news release that the companies aim to create an extendable platform to create specific solutions. These offerings provide patients with support and guidance throughout therapy. Ypsomed’s connected injection devices, including the SmartPilot for YpsoMate, come pre-integrated into the platform.

The platform itself offers versatility and customization ca…

Ypsomed, S3 Connected Health partner to expand digital offerings

[Image courtesy of Ypsomed and S3 Connected Health]Ypsomed announced plans to expand its offerings of digital health solutions for chronic disease therapy together with S3 Connected Health.

Dublin, Ireland-based S3 Connected Health specializes as a digital health partner for life science companies. This partnership allows Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. It enables therapy management support for acute and chronic diseases while enhancing outcomes.

Ypsomed said in a news release that the companies aim to create an extendable platform to create specific solutions. These offerings provide patients with support and guidance throughout therapy. Ypsomed’s connected injection devices, including the SmartPilot for YpsoMate, come pre-integrated into the platform.

The platform itself offers versatility and customization capabilities for any disease area and use case, the companies say.

Abbott FreeStyle Libre 3 authorized for automated insulin delivery in UK

[Image from Ypsomed]Abbott (NYSE:ABT) announced that its FreeStyle Libre 3 continuous glucose monitor (CGM) received UK authorization for use in automated insulin delivery.

Authorization enables FreeStyle Libre 3 — Abbott’s newest sensor — to work with the Ypsomed mylife YpsoPump and CamDiab’s CamAPS FX mobile app. The company called this a “major step forward” for type 1 diabetes management in the United Kingdom.

At the end of last year, the company received authorization to integrate FreeStyle Libre 3 with the mylife Loop from Ypsomed and CamDiab. That collaboration began in Germany. Abbott said at the time that it planned launches in the UK, Switzerland and the Netherlands in the first half of this year.

Combined, the technologies form an intelligent process to deliver insulin in the form of an artificial pancreas. The closed-loop system utilizes real-time glucose data to create an automated insulin delivery (AID) system. It remov…

The year ahead in diabetes care: what to expect in 2023

[Image courtesy of Walmart] After a banner year for diabetes technology in 2022, there’s still plenty to look forward to in 2023.

Throughout 2022, we saw a wide range of advancements in diabetes technology. We saw launches for next-generation technologies, exciting clinical trial results, rumored spinouts and acquisitions and more.

You can read all about the biggest diabetes stories of 2022 here.

As we embark on a new year in 2023, there’s still plenty to look forward to in the diabetes space. Here are a few things worth keeping an eye on.

CMS decision could benefit CGMs

In October, The Centers for Medicare and Medicaid Services (CMS) published a new local coverage determination (LCD). That LCD modified coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history of problematic hypoglycemia.

Analysts suggested at the time that the decision marked a win for …

Ypsomed, Mediq complete sale of DiaExpert

Ypsomed and Mediq announced today that they completed the sale of mail-order retailer for diabetes care DiaExpert.

Germany-based DiaExpert specializes in insulin pump therapy. The companies previously announced the sale of DiaExpert in October. This sale allows Ypsomed to focus on the manufacture and sale of its own medical technologies.

That focus continues to narrow after last month’s announcement of the discontinuation of Ypsomed’s agreement with Eli Lilly. Lilly elected to stop their joint collaboration to enter the U.S. insulin pump market.

Get the full story at our sister site, Drug Delivery Business News.

The 10 biggest diabetes tech stories from 2022

Some of the biggest diabetes technology developments in 2022. These include the Dexcom G7 (top left), Insulet Omnipod 5 (bottom left), Senseonics Eversense E3 (top right) and Abbott FreeStyle Libre 3 (bottom right. 2022 represented a landmark year for next-generation diabetes technologies. Here are the biggest stories from the past year.

Some companies picked up major regulatory nods. Others experienced major regulatory setbacks.

Partnerships were formed and ended, while mergers and acquisitions came and went. There were many stories to choose from, but here are 10 big ones that stood out:

Dexcom G7 receives FDA clearance

The long-awaited regulatory nod for Dexcom’s next-generation continuous glucose monitor (CGM) finally came in December.

Some suggested that San Diego-based Dexcom may pick up clearance as soon as summer 2022. However, a software change recommended by the FDA, plus COVID-19-related backlog, delayed proceedings.

Dexcom COO Ja…

Abbott FreeStyle Libre 3 links with automated insulin delivery system for use in Europe

The sensor for the next-generation FreeStyle Libre 3 CGM is the same size as two U.S. pennies stacked together. [Image courtesy of Abbott]Abbott (NYSE:ABT) today announced compatibility between its FreeStyle Libre 3 sensor and the mylife Loop from Ypsomed and CamDiab.

Combined, the technologies create a smart, automated process for insulin delivery based on real-time glucose data.

The companies launched their automated insulin delivery (AID) system in Germany. They intend to offer it in additional European countries in 2023.

“Our FreeStyle Libre portfolio is already helping to improve the lives of 4.5 million people around the world who are living with diabetes,” said Jared Watkin, SVP of Abbott’s diabetes care business. “We’re partnering with diabetes and digital health technology leaders like Ypsomed and CamDiab to deliver new innovative solutions that make diabetes care as easy as possible, so people can spend less time worr…